Yaseen Muhammad, Althaqafi Abdulhakeem, Farahat Fayssal, Alsaedi Asim, Mowallad Abdulfattah, Klein Eili, Tseng Katie, Essack Sabiha
Infection Prevention and Control, Velindre University National Health Service Trust, Cardiff, GBR.
Infectious Diseases, King Abdulaziz Medical City, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, SAU.
Cureus. 2022 Feb 13;14(2):e22168. doi: 10.7759/cureus.22168. eCollection 2022 Feb.
Assessing the effectiveness of antibiotics and communicating the problem of resistance are essential when devising antimicrobial stewardship programs (ASPs) in hospital settings. The Drug Resistance Index (DRI) is a useful tool that combines antibiotic consumption and bacterial resistance into a single measure. In this study, we used the DRI to assess the impact of introducing a new antibiotic restriction form on antibiotic effectiveness for the treatment of Gram-negative infections in the intensive care unit (ICU).
This was an observational study to assess and evaluate the antibiotic susceptibility of Gram-negative bacteria and antibiotic prescribing rates for the antibiotics indicated for Gram-negative bacteria following the introduction of a new antibiotic restriction form. The study was conducted from 2015 to 2017 at King Abdulaziz Medical City, a tertiary care facility in Jeddah, Saudi Arabia. Changes in antibiotic effectiveness before and after the introduction of the form were evaluated by calculating the DRI for four of the most common Gram-negative pathogens and eight commonly used antibiotic classes.
The overall DRI for the adult ICU was higher (59.45) in comparison to the hospital-wide DRI (47.96). A higher DRI was evident for carbapenems and antipseudomonal penicillins + beta-lactamase inhibitors. had the highest DRI followed by in both the adult ICU and hospital-wide. After the implementation of antibiotic restriction in the adult ICU, the DRI for carbapenems was significantly lower in the post-intervention phase (from 31.61 to 26.05) (p = 0.031).
The DRI is a useful tool for tracking the effectiveness of antibiotics over time. The results of our study are significant in the way that it highlights the importance of having an effective antibiotic stewardship program in healthcare settings and regular feedback of antibiotic consumption data to the stakeholders to keep the antibiotic prescriptions in check, thereby ensuring their sustained effectiveness.
在制定医院抗菌药物管理计划(ASP)时,评估抗生素的有效性并传达耐药性问题至关重要。耐药指数(DRI)是一种有用的工具,它将抗生素消耗和细菌耐药性结合为一个单一指标。在本研究中,我们使用DRI来评估引入一种新的抗生素限制表格对重症监护病房(ICU)中革兰氏阴性菌感染治疗的抗生素有效性的影响。
这是一项观察性研究,旨在评估和评价引入新的抗生素限制表格后革兰氏阴性菌的抗生素敏感性以及针对革兰氏阴性菌的抗生素处方率。该研究于2015年至2017年在沙特阿拉伯吉达的一家三级医疗设施阿卜杜勒阿齐兹国王医疗城进行。通过计算四种最常见革兰氏阴性病原体和八类常用抗生素的DRI,评估引入表格前后抗生素有效性的变化。
成人ICU的总体DRI(59.45)高于全院范围的DRI(47.96)。碳青霉烯类和抗假单胞菌青霉素+β-内酰胺酶抑制剂的DRI更高。在成人ICU和全院范围内, 的DRI最高,其次是 。在成人ICU实施抗生素限制后,碳青霉烯类的DRI在干预后阶段显著降低(从31.61降至26.05)(p = 0.031)。
DRI是一种用于长期跟踪抗生素有效性的有用工具。我们的研究结果具有重要意义,因为它突出了在医疗机构中制定有效的抗菌药物管理计划以及向利益相关者定期反馈抗生素消耗数据以控制抗生素处方从而确保其持续有效性的重要性。